

()

:

:_____

) IPH

:_____ .
()

IPH

:_____ .

% /

. % / % / / % / % / % /

()% / () IPH

(% CI: / - /) / IPH (OR) . ()% / ()% /

(% CI: / /) / (% CI: / - /) /

:_____ . (% CI: / - /) /

:

/ / : / / : / / :

ⁱADA

i- American Diabetes Association

:

E-mail:fhospanah@erc.ac.ir

(2h-PG)

OGTT

/

ADA

()

OGTT

OGTT

(/) Seca 707

IPH

ⁱⁱⁱBMI

() ()

IPH

ADA

OGTT ADA

/

)

(Cerestar EP

IPH

iii - Body Mass Index

i - Oral glucose tolerance test

ii - Isolated Postchallenge hyperglycemia

BMI

iii		Selectra 2 [®] autoanalyser (Vital Scientific, Spankeren, Netherlands).	
IPH			
HDL-C	TC (mg/dL)	(mg/dL)	(% / %)
(<)	(≥)	:	
(<)	(≥ BP /)	()	:
(<)	(≥)	(BP < /)	(% / %)
()	BMI ()	HDL ()	(% / % / % /)
()		B	
SPSS 11.5		:	()
	%	LDL (% / %)	
		LDL	
			TG
/		cat. no.)	
/		:1446070; Boehringer Mannheim; Germany	
/		(cat. no. 171778;	(ⁱ
/		ⁱⁱ	:Boehringer Mannheim; Germany)
/	()		
/			
/			
/			±
/		≤	
/	()		
/		>	
/		>	
/		> -	t
/		>	
/		> -	post hoc ANOVA
/		> -	
/		≤	
		HDL TC TG	FPG


iii- Adjusted Odds Ratio (OR)

i- Percinorm
 ii- Percipath

% / ()
 () % / IPH ()
 IPH FPG ()
 ± ±) () ()
 2hPG (p< /
 ±)
 .(p< / ±
 (%) IPH
 (%) / ± /
 IPH .(p< /) (% /)
 linear p< /)
 (by linear chi square test; $\chi^2 = 42.4$ % /
 () () % / % /
 IPH .()
 p< /
 (% /) .(p< / % / % /)
 FPG IPH (% /)
 FPG IPH (p< /
 ±) ± ±)
 .(p< / ± 2h-PG FPG .(p< /
 % /) .
 (% / (2h-PG=1.03 ×age + 71) (FPG=0.31×age + 79)
 FPG
)% / 2h-PG
)
 IPH (

()	() IPH	()	()
±	/ ± †	/ ± /	()
±	± †	± *	() TG
±	± †	± †	() TC
±	±	±	() HDL
±	± §	±	() LDL
±	± †	±	() SBP
±	± †	±	() DBP
/ ± /	/ ± / †	/ ± /	() BMI
/ ± /	/ ± / †	/ ± /	()
IPH	p< / † IPH	p< / † IPH	[< / * IPH p< / §

FPG
 % /
 2h-PG
 2h-PG
 % /
 % /
 ()
 2h-PG
 $[2h-PG=(1.9 \times FBS)+(0.4 \times Age)+(13.2 \times Sex)+(0.04 \times TG)+(0.23 \times SBP)+(0.18 \times Waist)-116.26]$



IPH
 IPH
 BMI ±
 TG
 IPH
 IPH
 (% CI: / /) /
 /
 CI: / /) /
 CI: / /) /
 (% CI: / /)
 (%
 TG (%
 HDL-C
 TG
 IPH
 *

Percent Contribution	SEM	†
/	/	() FBS
/	/	()
/	/	/
/	/	() TG
/	/	() SPB
/	/	()

.p< / † (p= /) TC (p= /) BMI (P= /) DBP R2 = / *

)

(

/ /

FPG

2h-PG

SBP TG

IFG IGT 2h-PG % /

2h-PG FPG

IPH

2h-PG FPG TG

2h-PG

2h-PG

FPG

2h-PG FPG

2h-PG

2h-PG FPG

2h-PG

DECODEⁱ

BMI 2h-PG

FPG TG SBP FPG

2h-PG

IGT

(/ /) / (/ /) (/ /)

% / / (/ /) / (/ /) / (/ /)

2h-PG

2h- (% /) /

(% /) PG /

(% % /)

% /)

BMI

(% /

% %

2SD 2h-PG

ⁱ - Diabetes Epidemiology Collaborative Analysis Of Diagnostic Criteria in Europe study

BMI

TG HDL

/ / i

(

(/)

(/)

()

IPH

(OR= /) FPG

TG (OR=)

(OR= /)

BMI

(OR=)

2h-PG

FPG IPH

%

2h-PG

FPG

2h-PG

IPH

2h-PG

% /

IPH %

FPG

% /

Strong Heart

% /

BMI SBP TG

IPH

IPH

%

FPG

FPG

2h-PG

IPH

2h-PG

ADA

IPH

IPH

FPG

OGTT

DECODE

OGTT

ADA

IFG

FPG

IPH

/

/

i- Hazard Ratio

IPH

IPH

FPG

2h-PG

FPG

IPH

FPG

OGTT

References

- Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS. Comparison of diabetes diagnostic categories in the US population according to 1977 American diabetes association and 1980-1985 world health organization diagnostic criteria. *Diabetes Care* 1997; 20:1859-62.
- Wahl PW, Savage PJ, Psaty BM, Orchard TJ, Robbins JA, Tracy RP. Diabetes in older adults: a comparison of 1997 American diabetes association classification of diabetes mellitus with the 1985 world health organization classification. *Lancet* 1998; 352:1012-15.
- Gomes-Peres FJ, Auguilar-Salinas CA, Lopez-Alvarenga JC, Perez-Juaregui J, Guillen -Pineda LE, Rull JA. Lack of agreement between the world health organization category of impaired glucose tolerance, and American diabetes association category of impaired fasting glucose. *Diabetes Care* 1998; 21: 1886-8.
- Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care* 1997; 20:1183-96.
- World Health Organization: Diabetes mellitus : Report of WHO study group. Geneva, World Health Org. 1985 Tech Rep Ser, no 727.
- Finch CF, Zimmet PZ, Alberti KG. Determining diabetes prevalence: a rational basis for the use of fasting plasma glucose concentration? *Diabet Med* 1990;7: 603-10.
- McCance DR, Hanson RL, Charles MA, Jacobsson LTH, Pettitt DJ, Bennett PH, et al. Comparison of tests for glycated hemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. *BMJ* 1994; 308: 1323-8.
- Engelgau MM, Thompson TJ, Herman WH, Boyle JP, Aubert RE, Kenny SJ, et al. Comparison of fasting and 2-hour glucose and HbA1c levels for diagnosing diabetes: diagnostic criteria and performance revisited. *Diabetes Care* 1997; 20: 785-91.
- Pomerleau J, McKeigue PM, Chaturvedi N. Relationships of fasting and postload glucose levels to sex and alcohol consumption. Are American Diabetes Association criteria biased against detection of diabetes in women? *Diabetes Care* 1999; 22: 430-3.
- Bando Y, Ushiogi Y, Okafuji K, Toya D, Tanaka N, Fujisawa M. The relationship of fasting plasma glucose value and other variables to 2-h postload plasma glucose in Japanese subjects. *Diabetes Care* 2001; 24:1156-60.
- DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group. Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. *BMJ* 1998; 317:371-5.
- Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men: the Rancho Bernardo Study. *Diabetes Care* 1998; 21: 1236-9.
- Hanefeld M, Koehler C, Schaper F, Fuecker K, Henkel E, Temelkova-Kurktschiev T. Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals. *Atherosclerosis* 1999; 144: 229-35.
- Kuizon D, Gordon SM, Dolmatch BL. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. *Arch Intern Med* 2001; 161: 397-405.
- de Veegt F, Dekker JM, Ruhe HG, Stehouwer CDA, Nijpels G, Bouter LM, et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population : the hoorn study . *Diabetologia* 1999; 42: 926-31.
- Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH. The natural history of impaired glucose tolerance in the Pima Indians. *N Engl J Med* 1988; 319: 1500-6.
- Meigs J, Nathan D, Wilson P, Cupples A, Singer D. Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance: the Framingham Offspring Study. *Ann Intern Med* 1998; 128: 524-33.
- Saydah SH, Miret M, Sung J, Varas C, Gause D, Brancati FL. Postchallenge hyperglycemia and

ADA WHO

- mortality in a national sample of U.S. adults. *Diabetes Care* 2001; 24: 1397-1402.
20. Shaw JE, Hodge AM, de Courten M, Chitson P, Zimmet PZ. Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. *Diabetologia* 1999; 42: 1050-4.
 21. Donahue RP, Abbott RD, Reed DM, Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. *Diabetes* 1987; 36: 689-92.
 22. Hanefeld M, Fischer S, Julius U, Schwanebeck U, Schmechel H, Ziegelasch HJ, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. *Diabetologia* 1996; 39: 1577-83.
 23. The Decode Study Group On Behalf Of The European Diabetes Epidemiology Group. Consequences of the new diagnostic criteria for diabetes in older men and women. DECODE Study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe. *Diabetes Care* 1999; 22: 1667-71.
 24. American Diabetes Association. Screening for type 2 diabetes. *Diabetes Care* 2004; 27 Suppl 1: S11-4.
 25. Azizi F, Rahmani M, Emami H, Madjid M. Tehran Lipid and Glucose Study. *CVD Prevention* 2000; 3: 242-7.
 26. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. *Endocrinol Metab Clin N Am* 2004; 33: 283-303.
 27. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 1972; 18: 499-502.
 28. Smith NL, Barzilay JI, Shaffer D, Savage PJ, Heckbert SR, Kuller LH, et al. Fasting and 2-hour postchallenge serum glucose measures and risk of incident cardiovascular events in the elderly: the Cardiovascular Health Study. *Arch Intern Med* 2002; 162: 209-16.
 29. de Vegt F, Dekker JM, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ. Similar 9-year mortality risks and reproducibility for the World Health Organization and American Diabetes Association glucose tolerance categories: the Hoorn Study. *Diabetes Care* 2000; 23: 40-4.
 30. The DECODE Study Group, European Diabetes Epidemiology Group: Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe: glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. *Lancet* 1999; 354: 617-21.
 31. Barzilay JI, Spiekerman CF, Wahl PW, Kuller LH, Cushman M, Furberg CD, et al. Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria. *Lancet* 1999; 354: 622-5.
 32. Rodriguez BL, Lau N, Burchfiel CM, Abbott RD, Sharp DS, Yano K, et al. Glucosa intolerance and 23-year risk of coronary heart disease and total mortality: the Honolulu Heart Program. *Diabetes Care* 1999; 22: 1262-5.
 33. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study. *Diabetes Care* 1999; 22: 920-4.
 34. Gabir M, Hanson RL, Debelea D, Imperatore G, Rousmain J, Bennett PH, et al. Plasma glucose and prediction of microvascular disease and mortality: evaluation of 1997 American Diabetes Association and 1999 World Health Organization criteria for diagnosis of diabetes. *Diabetes Care* 2000; 23: 1113-8.
 35. Balkau B, Forhan A, Eschwege E. Two hour plasma glucose is not unequivocally predictive for early death in men with impaired fasting glucose: more results from the Paris Prospective Study. *Diabetologia* 2002; 45: 1224-30.
 36. Meigs JB, Nathan DM, D'Agostino RB Sr, Wilson PW. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study *Diabetes Care* 2002; 25: 1845-50.
 37. Stern MP, Fatehi P, Williams K, Haffner SM: Predicting future cardiovascular disease: do we need the oral glucose tolerance test? *Diabetes Care* 2002; 25: 1851-6.
 38. DECODE Study Group, European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? *Diabetes Care* 2003; 26: 688-96.
 39. Andres R. Aging and diabetes. *Med Clin North Am* 1971; 55: 835-45.
 40. Andres R. Aging, diabetes, and obesity: standards of normality. *Mt Sinai J Med* 1981; 48: 489-95.
 41. Jackson RA. Mechanisms of age-related glucose intolerance. *Diabetes Care* 1990; 13: Suppl 2: 9-19.
 42. Ferrara A, Wingard DL, Barrett-Corner E, Shan J. Predictors of change in fasting plasma glucose (FPG) and postchallenge plasma glucose (PCPG) levels in older men and women: the Rancho Bernardo Study 1984-1994 (Abstract). *Diabetes* 1996;45: Suppl 2: 135A.
 43. Barrett-Corner E. Factors associated with the distribution of fasting plasma glucose in an adult community. *Am J Epidemiol* 1980; 112: 518-23.
 44. Sayetta RB, Murphy RS. Summary of current diabetes-related data from the National Center for Health Statistics. *Diabetes Care* 1979; 2: 105-19.
 45. Azizi F, Rahmani M, Emami H, Mirmiran P, Hajipour R, Madjid M, et al. Cardiovascular risk factors in an Iranian urban population: Tehran lipid and glucose study (phase 1). *Soz Pravent Med* 2002; 47: 408-26.
 46. Azizi F, Salehi P, Etemadi A, Zahedi-Asl S. Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study. *Diabetes Res Clin Pract* 2003; 61: 29-37.
 47. Azizi F, Ghanbarian A, Madjid M, Rahmani M. Distribution of blood pressure and prevalence of hypertension in Tehran adult population: Tehran Lipid and Glucose Study (TLGS), 1999-2000. *J Hum Hypertens* 2002; 16: 305-12.
 48. Azizi F, Rahmani M, Ghanbarian A, Emami H, Salehi P, Mirmiran P, et al. Serum lipid levels in an Iranian adults population: Tehran Lipid and Glucose Study. *Eur J Epidemiol* 2003; 18: 311-9.
 49. DeNino WF, Tchernof A, Dionne IJ, Toth MJ, Ades PA, Sites CK, et al. Contribution of abdominal adiposity to age-related differences in insulin sensitivity and plasma lipids in healthy nonobese women. *Diabetes Care* 2001; 24: 925-32.
 50. Imbeault P, Prins JB, Stolic M, Russell AW, O'Moore-Sullivan T, Despres JP, et al. Aging per se does not influence glucose homeostasis: in vivo and in vitro evidence. *Diabetes Care* 2003; 26: 480-4.
 51. Zavaroni I, Bonini L, Gasparini P, Barilli AL, Zuccarelli A, Dall'Aglio E, et al. Hyperinsulinemia in

-
- a normal population as a predictor of noninsulin-dependent diabetes mellitus, hypertension, and coronary heart disease: the Barilla factory revisited. *Metabolism* 1999; 48: 989-94.
52. Chen JW, Jen SL, Lee WL, Hsu NW, Lin SJ, Ting CT, et al. Differential glucose tolerance in dipper and nondipper essential hypertension: the implications of circadian blood pressure regulation on glucose tolerance in hypertension. *Diabetes Care* 1998; 21: 1743-8.
 53. Feldstein CA, Renauld A, Akopian M, Olivieri AO, Garrido D. Relationship between hyperinsulinemia and ambulatory blood pressure monitoring of lean and overweight male hypertensives. *J Cardiovasc Risk* 1998; 5: 25-30.
 54. Fujita Y, Kojima H, Hidaka H, Fujimiya M, Kashiwagi A, Kikkawa R. Increased intestinal glucose absorption and postprandial hyperglycemia at the early step of glucose intolerance in Otsuka Long-Evans Tokushima Fatty rats. *Diabetologia* 1998; 41: 1459-66.
 55. O'Donovan DG, Doran S, Feinle-Bisset C, Jones KL, Meyer JH, Wishart JM, et al. Effect of variations in small intestinal glucose delivery on plasma glucose, insulin, and incretin hormones in healthy subjects and type 2 diabetes. *J Clin Endocrinol Metab* 2004; 89: 3431-5.
 56. Lee ET, Howard BV, Go O, Savage PJ, Fabsitz RR, Robbins DC, et al. Prevalence of undiagnosed diabetes in three American Indian populations. A comparison of the 1997 American Diabetes Association diagnostic criteria and the 1985 World Health Organization diagnostic criteria: the Strong Heart Study. *Diabetes Care* 2000; 23: 181-6.
 57. Resnick HE, Harris MI, Brock DB, Harris TB. American Diabetes Association diabetes diagnostic criteria, advancing age, and cardiovascular disease risk profiles: results from the Third National Health and Nutrition Examination Survey. *Diabetes Care* 2000; 23: 176-80.
 58. Lowe LP, Liu K, Greenland P, Metzger BE, Dyer AR, Stamler J. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men. The Chicago Heart Association Detection Project in Industry Study. *Diabetes Care* 1997; 20: 163-9.
 59. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. *Diabetes Care* 1999; 22: 233-40.
 60. Suzuki H, Fukushima M, Usami M, Ikeda M, Taniguchi A, Nakai Y, et al. Factors responsible for development from normal glucose tolerance to isolated postchallenge hyperglycemia. *Diabetes Care* 2003; 26: 1211-5.
 61. Li CL, Tsai ST, Chou P. Comparison of metabolic risk profiles between subjects with fasting and 2-hour plasma glucose impairment. The Kinmen Study. *J Clin Epidemiol* 2002; 55: 19-24.